Hemogenyx’s Phase 1 AML Study: A Potential Game-Changer?

Hemogenyx Pharmaceuticals Plc ((GB:HEMO)) announced an update on their ongoing clinical study.

Hemogenyx Pharmaceuticals Plc is conducting a Phase 1 clinical study titled Phase 1 Study of Anti-FLT3 Chimeric Antigen Receptor-redirected T Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML). The study aims to assess the safety of anti-FLT3 CAR-T cells, known as HG-CT-1, in patients with relapsed or refractory AML. The primary goal is to determine the safety profile of HG-CT-1, while secondary objectives include evaluating its efficacy, overall survival, and progression-free survival.

The intervention being tested is Anti-FLT3 CAR-T cells, a type of drug administered via intravenous infusion following standard chemotherapy. This treatment is designed to target and eliminate cancer cells in patients with AML.

The study employs a non-randomized, sequential intervention model with no masking, focusing on treatment as the primary purpose. The trial uses a modified toxicity probability interval design to determine the appropriate dosing levels for adult and pediatric cohorts.

The study began on January 10, 2025, with the latest update submitted on August 11, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data being collected.

This study update could positively impact Hemogenyx’s stock performance and investor sentiment, as successful trials may lead to new treatment options for AML, a competitive area in oncology. Investors should watch for further developments, as positive outcomes could enhance Hemogenyx’s market position.

The study is currently recruiting, and further details are available on the ClinicalTrials portal.